IFNA1 and multiple sclerosis: A small subset (approximately 0.5%) of patients, mainly women, administered IFN-α or β for chronic myelogenous leukemia, multiple sclerosis or other conditions developed PAH, which could be reversed in some but not all patients by cessation of the IFN therapy [7,8,9].